Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2013

01.02.2013 | short review

Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic

verfasst von: Alexandra Kolenova, PhD, MD, Eva Bubanska, MD, PhD, Irina Oravkinova, MD, Zuzana Subova, MD, Martina Mikeskova, MD, Stanislava Hederova, MD, Dana Petrzalkova, MD, Zuzana Laluhova Striezencova, MD, MPH, Oksana Fabri, MD, Lucia Copakova, MD, Alica Chocholova, MD, Sabina Sufliarska, PhD, MD, Julia Horakova, PhD, MD, Prof. Jan Cap, PhD, MD, Anna Foltinova, PhD, MD, Daniela Sejnova, PhD, MD, Asso. Prof. Emilia Kaiserova, PhD, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute myeloid leukemia (AML) in children is rare, and it is generally considered to be more resistant to chemotherapy than acute lymphoblastic leukemia. However, because of the gradual intensification of chemotherapy and better supportive care, outcomes have improved considerably over the past 20 years. The management of children with AML in the Slovak Republic was unified and centralized during the second half of the 1990s with the introduction of Berlin-Frankfurt-Munster (BFM) protocols. In 2000, the AML-BFM-1998 protocol was introduced, and data collection became centralized.

Methods and results

Between 2000 and 2009, 73 patients (f = 38, m = 35) were treated according to the AML-BFM 1998. Complete remission (CR) was achieved in 89 % of the patients. The 5-year event-free-survival (EFS) and overall survival rates were 47 ± 6 % and 52 ± 6 %, respectively. The cumulative incidence of relapse was 38 %. The early death (ED) rate and the death rate in CR were both 7 %. The prognosis of children with favorable cytogenetics (standard risk (SR) group) tended to be better than the high-risk group (all other patients; EFS 63 vs. 40 %, p = 0.15). This tendency was supported by a significantly lower cumulative incidence of relapse in the SR-group (p = 0.008 by the log-rank test).

Conclusion

Unified treatment protocols and centralized diagnostics improved the management of pediatric AML in the Slovak Republic and increased the overall survival rate to 52 % in the total group and 68 % in children with a favorable cytogenetics. The high relapse rate and treatment-related mortality will be reduced by improving diagnostics, disease control, and the management of treatment-related complications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat [1] Chard RL, Finkelstein ZJ, Sonley MJ. Increased survival in childhood nonlymphoblastic leukemia after treatment with prednisone, cytosine arabinoside, 6 thiouganine, cyclophosphamide and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol. 1978;4:263–9.PubMedCrossRef [1] Chard RL, Finkelstein ZJ, Sonley MJ. Increased survival in childhood nonlymphoblastic leukemia after treatment with prednisone, cytosine arabinoside, 6 thiouganine, cyclophosphamide and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol. 1978;4:263–9.PubMedCrossRef
Zurück zum Zitat [2] Baehner RL, Kennedy A, Sather H. Characteristics of children with acute nonlympocytic leukemiain long-term continuous remission. A report of Children’s Cancer Study Group. Med Pediatr Oncol. 1981;9:393–403.PubMedCrossRef [2] Baehner RL, Kennedy A, Sather H. Characteristics of children with acute nonlympocytic leukemiain long-term continuous remission. A report of Children’s Cancer Study Group. Med Pediatr Oncol. 1981;9:393–403.PubMedCrossRef
Zurück zum Zitat [3] Weinstein HJ, Meyer RJ, Rosenthal DS, Camitta BM, et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980;303:473–8.PubMedCrossRef [3] Weinstein HJ, Meyer RJ, Rosenthal DS, Camitta BM, et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980;303:473–8.PubMedCrossRef
Zurück zum Zitat [4] Cáp J, Foltinova A, Misikova Z. Preliminary results of intensive treatment of pediatric acute myeloid leukemia according to treatment protocols. Česk Pediatr. 1984;39(3):509–12 (In Slovak).PubMed [4] Cáp J, Foltinova A, Misikova Z. Preliminary results of intensive treatment of pediatric acute myeloid leukemia according to treatment protocols. Česk Pediatr. 1984;39(3):509–12 (In Slovak).PubMed
Zurück zum Zitat [5] Creutzig U, Zimmermann M, Ritter J, Reinhardt D, et al. Treatment strategies and long term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030–42.PubMedCrossRef [5] Creutzig U, Zimmermann M, Ritter J, Reinhardt D, et al. Treatment strategies and long term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030–42.PubMedCrossRef
Zurück zum Zitat [6] Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children with acute myeloid leukemia: results of AML BFM 98. J Clin Oncol. 2006;24(27):4499–506.PubMedCrossRef [6] Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children with acute myeloid leukemia: results of AML BFM 98. J Clin Oncol. 2006;24(27):4499–506.PubMedCrossRef
Zurück zum Zitat [7] Creutzig U, Zimmermann M, Bourquin JP, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012;26(4):654–61.PubMedCrossRef [7] Creutzig U, Zimmermann M, Bourquin JP, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012;26(4):654–61.PubMedCrossRef
Zurück zum Zitat [8] Creutzig U, Zimmermann M, Bourquin JP, et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer. 2011;57(6):986–92.PubMedCrossRef [8] Creutzig U, Zimmermann M, Bourquin JP, et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer. 2011;57(6):986–92.PubMedCrossRef
Zurück zum Zitat [9] Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011;118(20):5409–15.PubMedCrossRef [9] Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011;118(20):5409–15.PubMedCrossRef
Zurück zum Zitat [10] Bene MC, Bernier M, Castoldi G, KnappW, et al. European Group for the Immunological characterization of leukaemias (EGIL). Proposals for the immunological classification of acute leukaemias. Leukemia. 1995;9:1783.PubMed [10] Bene MC, Bernier M, Castoldi G, KnappW, et al. European Group for the Immunological characterization of leukaemias (EGIL). Proposals for the immunological classification of acute leukaemias. Leukemia. 1995;9:1783.PubMed
Zurück zum Zitat [11] Cheson BD, Cassleth PA, Head DR, et al. Report of the National Canser Institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–9.PubMed [11] Cheson BD, Cassleth PA, Head DR, et al. Report of the National Canser Institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–9.PubMed
Zurück zum Zitat [12] Kolenova A, Kaiserova E, Sejnova D, et al. Pediatric acute myeloid leukemia in Slovak republic. Lek Obz. 2008;56:512–3 (In Slovak). [12] Kolenova A, Kaiserova E, Sejnova D, et al. Pediatric acute myeloid leukemia in Slovak republic. Lek Obz. 2008;56:512–3 (In Slovak).
Zurück zum Zitat [13] Kaiserova E, Bubanska E, Oravkinova I, et al. Incidence and curability of malignancies in childhood in Slovak republic. Onkologia (Bratislava). 2006;3(1):180–6 (In Slovak). [13] Kaiserova E, Bubanska E, Oravkinova I, et al. Incidence and curability of malignancies in childhood in Slovak republic. Onkologia (Bratislava). 2006;3(1):180–6 (In Slovak).
Zurück zum Zitat [14] Kaiserova E, Bubanska E, Oravkinova I, et al. Results of acute lymphoblastic treatment in children in the Slovak Republic. Memo. 2011;4:190–5.CrossRef [14] Kaiserova E, Bubanska E, Oravkinova I, et al. Results of acute lymphoblastic treatment in children in the Slovak Republic. Memo. 2011;4:190–5.CrossRef
Zurück zum Zitat [15] Rubnitz JE, Razzouk IB, Ribeiro RC. Acute myeloid leukemia. In: Pui CH et al., editors. Childhood leukemias. Cambrige: Cambrige University Press; 2006. pp. 499–539. [15] Rubnitz JE, Razzouk IB, Ribeiro RC. Acute myeloid leukemia. In: Pui CH et al., editors. Childhood leukemias. Cambrige: Cambrige University Press; 2006. pp. 499–539.
Zurück zum Zitat [16] Urbanova D, Bubanska E, Hrebik M, Mladosievicova B. Heart transplant in a childhood leukemia survivor: a case report. Exp Clin Transplant. 2010;8(1):79–81.PubMed [16] Urbanova D, Bubanska E, Hrebik M, Mladosievicova B. Heart transplant in a childhood leukemia survivor: a case report. Exp Clin Transplant. 2010;8(1):79–81.PubMed
Zurück zum Zitat [17] Kaspers GJL, Zwaan CHM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519–32.PubMedCrossRef [17] Kaspers GJL, Zwaan CHM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519–32.PubMedCrossRef
Zurück zum Zitat [18] Reinhardt D, Von Neuhoff C, Sander A, Creutzig U. Genetic prognostic factors in childhood acute myeloid Leukemia. Klin Padiatr. (in press). [18] Reinhardt D, Von Neuhoff C, Sander A, Creutzig U. Genetic prognostic factors in childhood acute myeloid Leukemia. Klin Padiatr. (in press).
Zurück zum Zitat [19] von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML BFM 98. J Clin Oncol. 2010;28:2682–9.PubMedCrossRef [19] von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML BFM 98. J Clin Oncol. 2010;28:2682–9.PubMedCrossRef
Metadaten
Titel
Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic
verfasst von
Alexandra Kolenova, PhD, MD
Eva Bubanska, MD, PhD
Irina Oravkinova, MD
Zuzana Subova, MD
Martina Mikeskova, MD
Stanislava Hederova, MD
Dana Petrzalkova, MD
Zuzana Laluhova Striezencova, MD, MPH
Oksana Fabri, MD
Lucia Copakova, MD
Alica Chocholova, MD
Sabina Sufliarska, PhD, MD
Julia Horakova, PhD, MD
Prof. Jan Cap, PhD, MD
Anna Foltinova, PhD, MD
Daniela Sejnova, PhD, MD
Asso. Prof. Emilia Kaiserova, PhD, MD
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0052-x

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe